Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II basket trial of pembrolizumab + vorinostat in recurrent or metastatic squamous cell carcinoma
2019-003839-33Phase 2Active
- Sponsor
- Unicancer
- Start
- Mar 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and vorinostat in head and neck squamous cell carcinoma (HNSCC), cervical squamous cell carcinoma (CSCC), Pulmonary squamous cell carcinoma and 3 more, sponsored by Unicancer. Primary endpoint: Objective response rate (ORR) by investigator assessment (RECIST v1.1). Started Mar 2020; status: active.
02
Drugs
pembrolizumabvorinostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)cervical squamous cell carcinoma (CSCC)Pulmonary squamous cell carcinomaanal squamous cell carcinoma (SCCA)vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on 2019-003839-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003839-33.